Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.11.003
Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.09.003
Development of a new Japanese guideline on drug interaction for drug development and appropriate provision of information.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.11.009
Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.12.002
Importance of cynomolgus monkeys in development of monoclonal antibody drugs.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.02.003
Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions part 3: Difference in substrate specificity of human and rodent CYP1A2 and the refinement of predicting system.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.02.001
Reconstitution of CYP3A4 active site through assembly of ligand interactions as a grid-template: Solving the modes of the metabolism and inhibition.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.10.001
Prediction of regioselectivity and preferred order of CYP1A1-mediated metabolism: Solving the interaction of human and rat CYP1A1 forms with ligands on the template system.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.10.008
Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.08.005
Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.04.002
Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.10.003
rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.10.007
Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.05.003
Quantitative investigation of hepatobiliary transport of [11C]telmisartan in humans by PET imaging.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.02.004
Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.08.004
Computational prediction of cytochrome P450 inhibition and induction.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.11.006
Riboflavin transport mediated by riboflavin transporters (RFVTs/SLC52A) at the rat outer blood-retinal barrier.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.08.002
Proteomic analysis of small intestinal epithelial cells in antibiotic-treated mice: Changes in drug transporters and metabolizing enzymes.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.01.001
Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.09.001
Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.08.001
Developmental changes in transporter and receptor protein expression levels at the rat blood-brain barrier based on quantitative targeted absolute proteomics.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.09.003
Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.10.005
Inhibitory kinetics of fruit components on CYP2C19 activity.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.02.002
Metabolomics study on the therapeutic effect of traditional Chinese medicine Xue-Fu-Zhu-Yu decoction in coronary heart disease based on LC-Q-TOF/MS and GC-MS analysis.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.07.004
The extent of drug-drug interaction between amlodipine and activated charcoal is attenuated by food intake in rats.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.08.008
Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.06.001
Pharmacokinetics and bioequivalence of low-dose clopidogrel in healthy Chinese volunteers under fasted and fed conditions.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.05.005
A spatial-temporal model for zonal hepatotoxicity of acetaminophen.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.09.266
Genotype-sensitive reversible and time-dependent CYP2D6 Inhibition in human liver microsomes
来源期刊：Drug Metabolism and PharmacokineticsDOI：10.1016/J.DMPK.2018.09.151
Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.10.001
Comparison of mRNA expression profiles of drug-metabolizing enzymes and transporters in fresh and cryopreserved cynomolgus monkey hepatocytes.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.04.003
Influence of gastrointestinal activity on the absorption of nilotinib.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.08.006
Organic anion-transporting polypeptide 1a4-mediated heterogeneous distribution of sulforhodamine-101 in rat hepatic lobules.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.04.001
Pharmacokinetic modeling and simulation for dose rationale of doripenem in neonates and infants.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.10.003
Effects of food type on the extent of drug-drug interactions between activated charcoal and phenobarbital in rats.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.05.002
Evaluation of drug-drug interactions in drug metabolism: Differences and harmonization in guidance/guidelines.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.10.006
Transport of 2,4-dichloro phenoxyacetic acid by human Na+-coupled monocarboxylate transporter 1 (hSMCT1, SLC5A8).
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2018.10.004
Development and validation of an LC-MS/MS method for vesicle assay using corning® Transportocells™ HEK293-derived ABC transporter membrane vesicles BCRP and MRP2
来源期刊：Drug Metabolism and PharmacokineticsDOI：10.1016/j.dmpk.2018.09.244
Physiologically based pharmacokinetic model predictions of ivosidenib (AG-120) as a victim and perpetrator of drug–drug interactions
来源期刊：Drug Metabolism and PharmacokineticsDOI：10.1016/j.dmpk.2018.09.238
Studies on the L-2-hydroxy-acid oxidase 2 catalyzed metabolism of S-mandelic acid and its analogues.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.02.003
Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.01.004
Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.05.001
Ex vivo whole liver perfusion model for prediction of drug-drug interactions and biliary excretion of rosuvastatin
来源期刊：Drug Metabolism and PharmacokineticsDOI：10.1016/J.DMPK.2018.09.172
Suppression of P-glycoprotein by cigarette smoke extract in human lung-derived A549/P-gp cells.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.12.001
Population pharmacokinetic and exposure-response analyses of guanfacine in Japanese pediatric ADHD patients.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/J.DMPK.2019.07.001
Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.11.007
pH-dependent transport kinetics of the human organic anion-transporting polypeptide 1A2.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.12.002
Pharmacokinetic assessment of alprazolam-induced neonatal abstinence syndrome using physiologically based pharmacokinetic model.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.09.002
Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.09.001
The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients.
来源期刊：Drug metabolism and pharmacokineticsDOI：10.1016/j.dmpk.2019.10.004
投稿咨询
加急服务
论文发表
2-4个月录用
7500+文章录用
不成功可退款
